Article
Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques.
Nature communications - 1 Sept 2021
Marlin Romain, Godot Veronique, Cardinaud Sylvain, Galhaut Mathilde, Coleon Severin, Zurawski Sandra, Dereuddre-Bosquet Nathalie, Cavarelli Mariangela, Gallouët Anne-Sophie, Maisonnasse Pauline, Dupaty Léa, Fenwick Craig, Naninck Thibaut, Lemaitre Julien, Gomez-Pacheco Mario, Kahlaoui Nidhal, Contreras Vanessa, Relouzat Francis, Fang Raphaël Ho Tsong, Wang Zhiqing, Ellis Jerome, Chapon Catherine, Centlivre Mireille, Wiedemann Aurelie, Lacabaratz Christine, Surenaud Mathieu, Szurgot Inga, Liljeström Peter, Planas Delphine, Bruel Timothée, Schwartz Olivier, Werf Sylvie van der, Pantaleo Giuseppe, Prague Mélanie, Thiébaut Rodolphe, Zurawski Gerard, Lévy Yves, Grand Roger Le
Abstract excerpt
Achieving sufficient worldwide vaccination coverage against SARS-CoV-2 will require additional approaches to currently approved viral vector and mRNA vaccines. Subunit vaccines may have distinct advantages when immunizing vulnerable individuals, children and pregnant women. Here, we present a new generation of subunit vaccines targeting viral antigens to CD40-expressing antigen-presenting cells. We demonstrate...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.